Events & Presentations

Investors

Events & Presentations

Upcoming Events
More events are coming soon.
Archived Events
Date Event Details
Nov 23, 2020 4:30 PM EST
Arrowhead Pharmaceuticals 2020 Year End Results
Nov 19, 2020 1:30 PM EST
ARO-ANG3 KOL Webinar
KOL: Ira Goldberg, M.D., New York University Langone School of Medicine
Nov 18, 2020 11:30 AM EST
ARO-APOC3 KOL Webinar
KOL: Christie Ballantyne, M.D., Baylor College of Medicine
Nov 17 - Nov 19, 2020
Jefferies Virtual London Healthcare Conference
November 19, 2020, 2:40 p.m. GMT – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation.
Nov 13 - Nov 16, 2020
The Liver Meeting Digital Experience, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
Title: ARO-AAT Reduces Serum and Intra-hepatic Z-AAT Protein in PIZZ Alpha-1 Antitrypsin Deficient Patients with Liver Disease Leading to Improvements in Clinically Relevant Liver Biomarkers
Authors: Pavel Strnad, et al.
Publication Number: LP14
Session: Late-breaking Abstract Posters
Nov 13 - Nov 17, 2020
American Heart Association (AHA) Scientific Sessions 2020

Title: Pharmacodynamic effect of ARO-ANG3, an investigational RNA interference therapeutic targeting hepatic angiopoietin-like protein 3, in patients with hypercholesterolemia
Authors: Gerald F. Watts, et al.
Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD

Title: Pharmacodynamic effect of ARO-APOC3, an investigational hepatocyte-targeted RNA interference therapeutic targeting apolipoprotein C3, in patients with hypertriglyceridemia and multifactorial chylomicronemia
Authors: Christie Ballantyne, presenting on behalf of Peter Clifton, et al.
Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD

Title: Safety, Tolerability and Efficacy of Single-Dose AMG 890, a Novel siRNA Targeting Lp(a), in Healthy Subjects and Subjects with Elevated Lp(a)
Authors: Michael J. Koren, et al.
Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD

Oct 8, 2020 8:30 AM EDT
Arrowhead/Takeda Collaboration Call
Oct 6, 2020 1:30 PM EDT
Chardan Virtual 4th Annual Genetic Medicines Conference
Vince Anzalone, CFA, Arrowhead’s vice president and head of investor relations, will participate in a fireside chat presentation
Sep 15, 2020 2:00 PM EDT
Cantor Fitzgerald Global Healthcare Conference 2020
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Sep 15, 2020 9:30 AM EDT
H.C. Wainwright 22nd Annual Global Investment Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation